ES2103809T3 - Polimeros como medios de contraste para la formacion de imagenes por resonancia magnetica. - Google Patents

Polimeros como medios de contraste para la formacion de imagenes por resonancia magnetica.

Info

Publication number
ES2103809T3
ES2103809T3 ES91908011T ES91908011T ES2103809T3 ES 2103809 T3 ES2103809 T3 ES 2103809T3 ES 91908011 T ES91908011 T ES 91908011T ES 91908011 T ES91908011 T ES 91908011T ES 2103809 T3 ES2103809 T3 ES 2103809T3
Authority
ES
Spain
Prior art keywords
magnetic resonance
polymers
images
formation
contrast means
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91908011T
Other languages
English (en)
Inventor
Evan C Unger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImaRx Pharmaceutical Corp
Original Assignee
ImaRx Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImaRx Pharmaceutical Corp filed Critical ImaRx Pharmaceutical Corp
Application granted granted Critical
Publication of ES2103809T3 publication Critical patent/ES2103809T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1803—Semi-solid preparations, e.g. ointments, gels, hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Signal Processing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Graft Or Block Polymers (AREA)

Abstract

SE DESCRIBEN MEDIOS CONTRASTANTES NUEVOS PARA SU USO EN LA FORMACION DE IMAGENES POR RESONANCIA MAGNETICA. TALES AGENTES CONTRASTANTES ESTAN FORMADOS POR POLIMEROS BIOCOMPATIBLES BIEN SOLOS BIEN EN MEZCLA CON UNO O MAS AGENTES CONTRASTANTES TALES COMO LOS AGENTES PARAMAGNETICOS, SUPERPARAMAGNETICOS O DE DENSIDAD PROTONICA. ADICIONALMENTE, SE PUEDEN MEZCLAR LOS POLIMEROS O POLIMERO Y EL AGENTE CONTRASTANTE CON UNO O MAS GASES BIOCOMPATIBLES PARA INCREMENTAR LA RELAJABILIDAD DE LA PREPARACION RESULTANTE.
ES91908011T 1990-04-10 1991-04-09 Polimeros como medios de contraste para la formacion de imagenes por resonancia magnetica. Expired - Lifetime ES2103809T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50712590A 1990-04-10 1990-04-10

Publications (1)

Publication Number Publication Date
ES2103809T3 true ES2103809T3 (es) 1997-10-01

Family

ID=24017359

Family Applications (2)

Application Number Title Priority Date Filing Date
ES91908011T Expired - Lifetime ES2103809T3 (es) 1990-04-10 1991-04-09 Polimeros como medios de contraste para la formacion de imagenes por resonancia magnetica.
ES95111117T Expired - Lifetime ES2138122T3 (es) 1990-04-10 1991-04-09 Polimeros como medios de contraste para resonancia magnetica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES95111117T Expired - Lifetime ES2138122T3 (es) 1990-04-10 1991-04-09 Polimeros como medios de contraste para resonancia magnetica.

Country Status (8)

Country Link
EP (2) EP0526503B1 (es)
JP (1) JPH05506227A (es)
AT (2) ATE185489T1 (es)
DE (2) DE69126429T2 (es)
DK (1) DK0526503T3 (es)
ES (2) ES2103809T3 (es)
GR (1) GR3023806T3 (es)
WO (1) WO1991015753A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
DK0531421T3 (da) * 1990-06-01 1998-01-12 Imarx Pharmaceutical Corp Kontrastmedier til ultralydsimagografi
US5420176A (en) * 1990-06-01 1995-05-30 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
US5948387A (en) * 1990-06-01 1999-09-07 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
AU667491B2 (en) * 1991-11-19 1996-03-28 Imarx Pharmaceutical Corp. Gel particle contrast media for improved diagnostic imaging
US5514379A (en) * 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5323780A (en) * 1992-08-07 1994-06-28 University Of Florida Research Foundation, Inc. Artifact-free imaging contrast agent
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
WO1994005203A1 (en) * 1992-09-04 1994-03-17 The General Hospital Corporation Biocompatible polymers containing diagnostic or therapeutic moieties
AU5355094A (en) * 1992-10-14 1994-05-09 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
EP0664819B1 (en) * 1992-10-14 1997-08-06 Nycomed Imaging As Chelating polymers
US5756688A (en) * 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
EP0783325B2 (en) 1994-09-27 2004-03-31 Amersham Health AS Contrast agent
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
WO1999052564A1 (en) * 1998-04-09 1999-10-21 Nycomed Imaging A.S Method
DE19942278C2 (de) * 1999-09-04 2001-09-13 Messer Griesheim Gmbh Quantitative Bestimmung des Xenongehaltes in Flüssigkeiten mit Hilfe der NMR-Spektroskopie
BRPI0619436A2 (pt) 2005-12-05 2011-10-04 Nitto Denko Corp métodos e conjugados de aminoácido-poliglutamato
US20090162291A1 (en) * 2006-05-17 2009-06-25 Otsuka Pharmaceutical Co., Ltd. Magnetic resonance contrast medium using polyethylene glycol and magnetic resonance image pick-up method
KR20100017540A (ko) 2007-05-09 2010-02-16 닛토덴코 가부시키가이샤 소수성 화합물 및 폴리아미노산 콘쥬게이트를 포함하는 조성물
KR101303567B1 (ko) * 2011-03-08 2013-09-23 주식회사 인트론바이오테크놀로지 카르복실기가 도입된 만난으로 코팅된 자기공명영상 조영제 및 그것의 제조 방법
EP3240579B1 (en) 2014-12-31 2022-07-27 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
CN115531560B (zh) 2016-05-04 2024-05-17 蓝瑟斯医学影像公司 用于制备超声波造影剂的方法及装置
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069306A (en) * 1974-03-14 1978-01-17 Pharmacia Aktiebolag X-ray contrast preparation containing a hydrophilic polymer containing amino groups
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
US4775522A (en) * 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
DE3316703A1 (de) * 1983-05-04 1984-11-08 Schering AG, 1000 Berlin und 4709 Bergkamen Orales kontrastmittel fuer die kernspintomographie und dessen herstellung
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
EP0184899B1 (en) * 1984-11-01 1990-04-18 Nycomed As Paramagnetic contrast agents for use in "in vivo" diagnostic methods using nmr, and their preparation
US4849210A (en) * 1985-05-08 1989-07-18 Molecular Biosystems, Inc. Magnetic resonance imaging of liver and spleen with superparamagnetic contrast agents
JPS62153229A (ja) * 1985-12-27 1987-07-08 Nippon Oil Co Ltd 皮膚マ−カ−
US4871716A (en) * 1986-02-04 1989-10-03 University Of Florida Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4729892A (en) * 1986-03-21 1988-03-08 Ciba-Geigy Corporation Use of cross-linked hydrogel materials as image contrast agents in proton nuclear magnetic resonance tomography and tissue phantom kits containing such materials
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4933441A (en) * 1987-01-27 1990-06-12 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
US4838274A (en) * 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
GB8813425D0 (en) * 1988-06-07 1988-07-13 Hall L D Magnetic resonance imaging
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US4996041A (en) * 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
GB8916780D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions

Also Published As

Publication number Publication date
EP0526503B1 (en) 1997-06-04
DK0526503T3 (da) 1997-10-27
ATE153860T1 (de) 1997-06-15
DE69126429T2 (de) 1997-10-23
WO1991015753A1 (en) 1991-10-17
EP0526503A1 (en) 1993-02-10
JPH05506227A (ja) 1993-09-16
EP0693288A1 (en) 1996-01-24
EP0693288B1 (en) 1999-10-13
EP0526503A4 (en) 1993-02-24
DE69131721T2 (de) 2000-03-02
DE69126429D1 (de) 1997-07-10
ATE185489T1 (de) 1999-10-15
DE69131721D1 (de) 1999-11-18
GR3023806T3 (en) 1997-09-30
ES2138122T3 (es) 2000-01-01

Similar Documents

Publication Publication Date Title
ES2103809T3 (es) Polimeros como medios de contraste para la formacion de imagenes por resonancia magnetica.
ES2112859T3 (es) Medios de contraste para la formacion de imagenes ecograficas.
DE69231830D1 (de) Gasgefüllte Mikrospheren enthaltende Kontrastmittel zur diagnostischen Bilderzeugung
ES2093077T3 (es) Construcciones de colageno.
DE59005714D1 (de) Verfahren zur Herstellung wässriger Polymerisatdispersionen.
FR2624728B1 (fr) Recipients pour matieres sales, telles qu'excretions d'un anus artificiel
FI955525L (fi) Pintamodifioituja, biologisesti yhteensopivia kalvoja
FI941173A7 (fi) Menetelmä vettä sisältävän polymeeridispersion valmistamiseksi
FI924019L (fi) Menetelmä vesipitoisen suspensiovalmisteen tuottamiseksi
TW222000B (es)
DE69104114D1 (de) System zur Auswertung der optischen Dispersion.
DE68904582D1 (de) Elektroakoustische membran und verfahren zur herstellung.
DE69001882D1 (de) Vorrichtung zur fahrzeugaufhaengung.
IT9067588A0 (it) Apparecchiatura atta ad accertare e misurare le condizioni di efficienza fisica di utenti di autoveicoli e le capacita' di guida degli stessi con e senza l'ausilio di adattamenti e/o protesi.
DE69003771D1 (de) Verfahren zur Herstellung Mangandioxydkatalysators zur Hydrierung von Cyanhydrinen.
ES513187A0 (es) "procedimiento para la obtencion de una suspension acuosa de carbon".
DE69016071D1 (de) Verfahren zur Augen-Diagnostik.
DE69013700D1 (de) Optische Trägerplatte, optisches Informationsspeichermedium und Verfahren zur Herstellung der optischen Trägerplatte.
DE3674554D1 (de) Verfahren zur justierfreien herstellung eines elektromagnetischen relais.
DE3868285D1 (de) Vorrichtung zur verhinderung von schneeklumpenbildung innerhalb des hufeisens eines beschlagenen hufes.
DE69001881D1 (de) Vorrichtung zur fahrzeugaufhaengung.
DE59007359D1 (de) Verfahren zur herstellung von 4,4'-dihydroxydiphenylsulfon.
ES507473A0 (es) Procedimiento para producir particulas polimericas expansio-nables mediante polimerizacion en suspension.
ATE103823T1 (de) Pumpe zur biomedizinischen verwendung.
DE59304579D1 (de) Verfahren zur Herstellung von 1,3-Dialkyl-5-hydroxyoxindolen und deren Etherderivaten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 526503

Country of ref document: ES